Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days
1-14 when given with topotecan on days 1-5 of every 21 day cycle Phase II will commence once
the MTD is established, additional subjects will be enrolled and receive oral lenalidomide on
days 1-14 with topotecan on days 1-5 in 21 day cycles until disease progression is
documented.